Biogen Inc. diskutieren
Biogen Inc.
WKN: 789617 / Symbol: BIIB / Name: Biogen / Aktie / Pharmazeutika / Large Cap /
162,65 €
-3,20 %
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $177.00 to $207.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Stifel Nicolaus from $202.00 to $214.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at TD Cowen.
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Royal Bank Of Canada from $217.00 to $233.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for BIIB provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in Silgan Holdings Inc. diskutieren